Heart failure
Conditions
Interventions
Heart failure patients with fluid retention scheduled to receive torvaptan:The drug tovaptan
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Sign informed consent; 2. Male and female, aged 18-85; 3. Patients clinically diagnosed with heart failure; 4. Symptoms of fluid retention such as lower limb edema, lung stasis or jugular vein irritation.
Exclusion criteria
Exclusion criteria: 1. No informed consent is signed; 2. Patients who are allergic to tovaptan or similar compounds; 3. Other contraindications associated with the use of tovaptan; 4. No urination, urinary obstruction caused by urethral stricture, calculus, tumor, etc.; 5. Abnormalities in any of the following laboratory tests: serum creatinine > 2.5 times the upper limit of normal, serum sodium > 145mmol/L, serum potassium > 5.5mmol/L; 6. Poorly controlled diabetes mellitus with fasting blood glucose exceeding 12.21mmol/L; 7. Pregnant women, lactating women, patients who may become pregnant or plan to become pregnant; 8. Acute myocardial infarction, persistent ventricular tachycardia or ventricular fibrillation, or cerebrovascular accident within 30 days before screening; 9. Diagnosis of active myocarditis or amyloid cardiomyopathy; 10. Decreased circulating blood volume, obstructive hypertrophic cardiomyopathy, and severe aortic stenosis are suspected; 11. Use of tovaptan within the first 3 months of study enrollment, including marketed tovaptan or in clinical studies; 12. In addition to the above, the investigator determined that the patients were not suitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine volume;Body weight;Serum sodium; | — |
Countries
China
Contacts
Public ContactXiaoYang Liao
West China Hospital, Sichuan University
Outcome results
None listed